Related Experiment Videos
A lipid hypothesis: prediction, observation and the triglyceride/HDL gap
1BARC Asia Pacific Pte Ltd, Jakarta.
Abstract:
Lowering serum lipid levels prevents myocardial infarctions. But are we targeting the right lipoproteins in our preventive therapy? Are we getting the maximum benefit? Triglycerides certainly deserve more attention than they have yet received. Most of the trials of lipid-lowering therapy have ignored them and this omission may explain the divergence between the fall in morbidity predicted from the epidemiological evidence and the reductions observed in the clinical trials. The evidence that the statins reduce coronary morbidity and mortality, and that this reduction is associated with a fall in LDL cholesterol, is overwhelming. But the potential value of the statins may be limited by their relative inability to increase the concentration of cardioprotective HDL. The fibrates, either alone, or in combination with a statin, retain a central role in the management of patients with mixed hyperlipidaemia who are undoubtedly at high risk of premature coronary artery disease.
Insights
Triglycerides, often overlooked in lipid-lowering therapy, warrant greater attention for preventing heart attacks. Focusing on triglycerides alongside LDL cholesterol may enhance cardiovascular disease prevention strategies.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Preventive Cardiology
Background:
- Lowering serum lipids is crucial for preventing myocardial infarctions.
- Current lipid-lowering therapies primarily focus on LDL cholesterol.
- The role of triglycerides and HDL cholesterol in cardiovascular prevention requires further investigation.
Purpose of the Study:
- To evaluate the significance of triglycerides in lipid-lowering therapy.
- To assess the limitations of statins in increasing HDL cholesterol.
- To determine the role of fibrates in managing mixed hyperlipidaemia for cardiovascular risk reduction.
Main Methods:
- Review of clinical trials and epidemiological evidence on lipid-lowering therapies.
- Analysis of the impact of statins on coronary morbidity and mortality.
- Evaluation of the efficacy of fibrates, alone or in combination with statins.
Main Results:
- Triglycerides have been largely ignored in major lipid-lowering trials.
- The omission of triglyceride management may explain discrepancies between predicted and observed reductions in clinical trials.
- Statins effectively reduce LDL cholesterol but have limited impact on HDL cholesterol.
Conclusions:
- Triglycerides require greater consideration in preventive cardiovascular therapy.
- Fibrates play a key role in managing mixed hyperlipidaemia and reducing high cardiovascular risk.
- Optimizing lipid management strategies may involve targeting multiple lipoprotein fractions for maximum benefit.